. Author manuscript; available in PMC: 2023 Mar 23.

Published in final edited form as: Kidney Int. 2022 Jun 16;102(3):624–639. doi: 10.1016/j.kint.2022.05.021

Table 4: Genetic risk score (GRS) analyses for end-stage kidney disease (ESKD) and Acute Kidney Injury (AKI).

In 3 case-control studies for ESKD and one for AKI, we computed the weighted GRS across the 9 eGFR-decline variants (counting the faster-decline alleles, weighted by effect size for eGFR-decline unadjusted for eGFR-baseline; divided by sum of weights and multiplied by 9, i.e. scaled as 0 to 18). Shown are odds ratios (OR), 95% confidence intervals (CI) and P-values (one-sided) for the quantitative GRS association (per 5 “average” unfavorable alleles) and for a high versus low GRS association (≥95^th versus ≤5^th, ≥90^th versus ≤10^th GRS percentiles derived in UK Biobank) with (A) ESKD and (B) AKI. Associations are derived by logistic regression adjusted for matching variables age-group and sex (AKI additionally for principal components).

		Per 5 unfavorable average alleles			High versus low GRS group
		Per 5 unfavorable average alleles			5% versus 95%			10% versus 90%
Study	Number of Cases	Number of Controls	OR	95% CI	P (1-sided)	OR	95% CI	P (1-sided)	OR	95% CI	P (1-sided)
(A) ESKD (cases: ICD10 code N18.0 or N18.5; controls: no ICD10 code N18, eGFR>60 mL/min/1.73m², frequency-matched by age-group and sex)
4D_KORA-F3	1,100	1,601	1.122	0.925,1.362	0.121	1.26	0.669,2.377	0.237	1.526	0.978,2.379	0.0313
GENDIAN_KORA-F4	470	1,545	1.146	0.923,1.423	0.108	0.954	0.468,1.946	0.449	1.036	0.625,1.719	0.445
UKBBCa_co	498	1,494	1.085	0.885,1.330	0.216	1.220	0.639,2.329	0.273	1.479	0.921,2.373	0.0525

Meta-analysis	2,068	4,640	1.117	0.993,1.256	0.0329	1.150	0.785,1.686	0.236	1.349	1.027,1.773	0.0157



(B) AKI (cases: ICD 10 code N17; controls: no ICD10 code N17, eGFR>60 mL/min/1.73m², frequency-matched by age-group and sex)

UKBBCaCo	3,878	11,634	1.179	1.095,1.270	6.47×10⁻⁰⁶	1.524	1.204,1.931	4.70×10⁻⁰⁴	1.272	1.080,1.499	1.97×10⁻⁰³

Study=Study name, OR=Odds Ratio of the GRS-association, 95% CI=95% confidence interval of the association, P (1-sided)=1-sided association P-value, ESKD=End-stage Kidney Disease, Individuals analyzed here are distinct from the eGFR-decline GWAS except for the KORA-F3 and KORA-F4 controls. AKI=Acute Kidney Injury, UKBBCaCo=cases and controls from UK Biobank distinct from UK Biobank study participants used in the GWAS for eGFR decline.